Xi Yan

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 169 citations

Medicine, Oncology, Pharmacology +12

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Pin Zhang, Qingyuan Zhang, Zhongsheng Tong et al. · The Lancet Oncology · 2023 · 95 citations

Medicine, Oncology, Pharmacology +16

Clinical characteristics of 45 patients with invasive pulmonary aspergillosis

Xi Yan, Mei Li, Ming Jiang et al. · Cancer · 2009 · 92 citations · Full text

Medicine, Oncology, Pathology +14

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy

Qianmei Yang, Gang Shi, Xiaolei Chen et al. · Theranostics · 2020 · 79 citations · Full text

Medicine, Immunology, Oncology +17

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

Binghe Xu, Yongmei Yin, Ying Fan et al. · Journal of Clinical Oncology · 2024 · 45 citations

Medicine, Oncology, Pharmacology +17